Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 4,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $22.57, for a total transaction of $95,922.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total transaction of $98,515.00.
• On Friday, May 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00.
• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total transaction of $346,080.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $22.70 on Tuesday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -11.76 and a beta of 1.11. The firm’s 50 day simple moving average is $21.77 and its 200 day simple moving average is $17.88. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. Equities research analysts expect that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on ELVN. Mizuho began coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Finally, Robert W. Baird began coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 target price on the stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently bought and sold shares of the stock. AJOVista LLC acquired a new stake in Enliven Therapeutics during the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Enliven Therapeutics in the fourth quarter valued at approximately $66,000. Exchange Traded Concepts LLC raised its holdings in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after purchasing an additional 2,208 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at approximately $167,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after buying an additional 1,029 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.